Xencor | XNCR - Betriebsaufwand





Betriebsaufwand Veränderung Datum
AbbVie USD 10.27B 1000K 2026-06
Alnylam Pharmaceuticals USD 1.06B 160.97M 2026-06
Amgen USD 11.69B 6.9B 2026-06
Arrowhead Research USD 245.35M 30.35M 2026-06
AstraZeneca USD 12.22B 4.04B 2026-06
Biogen USD 2.98B 1.02B 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Cytokinetics USD 207.8M 7.22M 2026-06
GlaxoSmithKline GBP 5.8B 468M 2026-06
J&J USD 17.83B 388M 2026-06
Karyopharm Therapeutics USD 61.83M 9.9M 2026-03
MacroGenics USD 42.87M 21.68M 2026-06
Merck USD 15.77B 2.4B 2026-06
Novartis USD 10.2B 912M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Roche Holding CHF 18.9B 2.12B 2026-06
Xencor USD 87.82M 5.44M 2026-06